Back

Glabridin improves cardiac remodeling after myocardial infarction by activating PPAR to regulate the ubiquitination and degradation of EGFR

14 April 2026 (08:00 - 14:45)
Organised by: Logo
Congress Presentation Part of: Poster session (3): mechanisms and management of arrhythmias Cardiac Diseases EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Zixuan Li

State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular D, Beijing (China)

188 More presentations in this session

Presentation thumbnail
Comparison of ECG findings between young patients with cryptogenic ischemic stroke and stroke-free control subjects
Doctor J. Uutela (Jyvaskyla, FI)
Abstract
Presentation thumbnail
A wearable SCG-based approach for early, low-cost screening of valvular heart disease
Doctor V. Pergola (Naples, IT)
Presentation thumbnail
Intraoperative assessment of cardiac parasympathetic tone using short-term HRV metrics before and after atropine administration: a pilot study
Doctor B. Hrymniak (Wroclaw, PL)
Abstract
Presentation thumbnail
Arrhythmia phenotypes in hair-loss therapies: insights from minoxidil and finasteride reports in eudravigilance
Doctor Y. Shhab (Bucharest, RO)
Abstract
Presentation thumbnail
Arrhythmias and device therapy in HFpEF: Insights from a real-world hospital cohort
Ms A. Bondoc (Timisoara, RO)
Abstract Slides Video

Access the full session

Session thumbnail
Poster session (3): mechanisms and management of arrhythmias

The Event

Event poster

EHRA 2026

14 April 2026 08:00 CET
You may be interested in
thumbnail
Congress Session
Young Investigator Award Session in Basic and Translational Sciences
30 August 2024
thumbnail
Congress Presentation
Head to head comparison of semaglutide and colchicine for treating atrial remodeling in post-MI rats with reduced ejection fraction
29 August 2025
thumbnail
Congress Presentation
MitoQ attenuates cardiomyocyte hypertrophy and collagen deposition in post-myocardial infarction remodelling
29 August 2025
thumbnail
Congress Presentation
A newly developed small-molecule ErbB4 agonist reduces reactive cardiac fibrosis and adverse ventricular remodelling after myocardial infarction in a sex-specific manner.
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources